CCEL Insider Buying: David Portnoy Acquires Shares and Holds Multiple Options
Rhea-AI Filing Summary
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company's common stock on September 16-18, 2025. He acquired 6,449 shares on 09/16/2025 at a weighted average price of $4.46, 5,564 shares on 09/17/2025 at $4.43, and 3,411 plus 1,751 shares on 09/18/2025 at weighted averages around $4.46 and $4.49 respectively. After these transactions his reported direct beneficial ownership in common stock reached 827,344 shares, and he also reports additional indirect holdings
Positive
- Chairman and Co-CEO purchased additional common stock, acquiring 17,175 shares on 09/16-09/18/2025 at weighted average prices between $4.43 and $4.49
- Direct beneficial ownership increased to 827,344 shares, indicating substantial insider stake
- Detailed option disclosures provided with exercise prices and vesting schedules through 2030, improving transparency
Negative
- None.
Insights
TL;DR: Significant insider purchases and large aggregated ownership increase direct stake to 827,344 shares; options add further upside exposure.
The Form 4 shows the company's chairman and co-CEO purchased a total of 17,175 shares across three reporting dates at weighted-average prices between $4.43 and $4.49, increasing his reported direct ownership to 827,344 shares and reflecting meaningful insider accumulation. The filing also details numerous indirect holdings across corporate, retirement and custodial accounts, and a portfolio of stock options with exercise prices from $4.30 to $12.27 and expirations through 2030. From a capital-structure viewpoint, the combination of direct holdings, indirect interests and vested/vesting options means the reporting person retains concentrated exposure to CCEL equity.
TL;DR: Routine Section 16 disclosure documenting insider purchases and option holdings; material for governance transparency.
The Form 4 is a standard Section 16 filing from a director and 10% owner documenting open-market purchases and existing derivative positions. It clarifies the nature of indirect holdings (corporate entities, retirement accounts, custodial accounts) and provides option vesting schedules and prices. The disclosure improves transparency about the reporting person's economic interests and potential conflicts, but contains no information about changes to governance, compensation, or corporate control beyond the ownership details presented.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 3,411 | $4.46 | $15K |
| Purchase | Common Stock | 1,751 | $4.49 | $8K |
| Purchase | Common Stock | 5,564 | $4.43 | $25K |
| Purchase | Common Stock | 6,449 | $4.46 | $29K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.40 to $4.47, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.41 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.
